Global Neurodegenerative Drugs Market to Exceed $43.4 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on neurodegenerative drugs markets. The world market for neurodegenerative drugs is projected to exceed $43.4 billion by the year 2015. This is primarily driven by a rapid global rise in aging population and associated increase in neurodegenerative diseases, particularly Alzheimer's and Parkinson's, as well as high degree of unmet medical needs in almost all major segments of the market.
San Jose, CA (PRWEB) April 12, 2010 -- Neurodegenerative diseases, caused due to neuron deficiency or dysfunction of the spinal cord or brain cells, are destructive in nature, as regeneration of affected cells is not possible and results in ultimate damage or death. Major neurodegenerative diseases with significant unmet medical needs include Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's disease. There are only a few treatment available for some of these diseases, and several of these treatment options provide only symptomatic relief. For a few others such as the Huntington's disease, there is still not a single therapy available that can treat the disease.
The United States dominates the world neurodegenerative drugs market as stated by the new market research report on Neurodegenerative Drugs market. The market exhibits huge potential considering the high rates of prevalence of Alzheimer's and Parkinson's disease. The market is largely untapped due to under-diagnosis owing to lack of proper diagnostics, and lack of therapies that can effectively and safely prevent or treat the diseases.
Neurodegenerative Drugs: A Global Strategic Business Report
Multiple Sclerosis represents the largest segment of the neurodegenerative drugs market. The multiple sclerosis drugs market is all set for a major transformation with new drugs in pipeline awaiting approval in near future. Most pipeline drugs are showing promising results in terms of reducing disease progression and other end-points compared to existing drugs. The most promising multiple sclerosis candidates include oral therapies such as Sanofi-aventis' Teriflunomide, Active Biotech's Laquinimod, Merck's Cladribine and Novartis' FTY720.
Alzheimer's is the fastest growing segment of the neurodegenerative drugs market. The currently available drugs for Alzheimer's disease not only provide limited efficacy, but may also result in serious adverse effects. There are issues with acceptability and safety, and some patients may even fail to respond to treatment with available drugs. The outlook appears interesting considering that a few leading products are lined up for patent expiry, including Namenda and Exelon, while there are others in pipeline that promise to deliver on the failure of available therapies.
Key players profiled in the report include Amarin Corporation Plc; AstraZeneca Plc; Avanir Pharmaceuticals Inc.; Avigen Inc.; Bayer Schering Pharma AG; Boehringer Ingelheim GmbH; Biogen Idec Inc.; Bristol-Myers Squibb Co.; Biovail Corporation; Ceregene, Inc.; Eisai, Inc.; Elan Pharmaceuticals; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline plc; H. Lundbeck A/S; Merz Pharmaceuticals GmbH; Merck Serono; Mitsubishi Tanabe Pharma Corporation; Neurologix, Inc.; NeuroSearch A/S; Novartis AG; Pfizer Inc.; Sanofi-aventis S.A.; Shire Pharmaceuticals Group Plc; Teva Pharmaceutical Industries Limited; Valeant Pharmaceuticals International; and Wyeth Pharmaceuticals, Inc.
The report titled "Neurodegenerative Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, market drivers, market inhibitors, competitive scenario, clinical trials, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe and Rest of World. The study analyzes market data and analytics in terms of value sales for neurodegenerative drugs by disease type, including Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Diseases.
For more details about this comprehensive market research report, please visit -
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/